MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 13, 2007; DOI: 10.1124/mol.107.041616


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041616v1
73/3/949    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, L.
Right arrow Articles by Mao, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, L.
Right arrow Articles by Mao, Q.


Received for publication September 6, 2007.
Revised November 22, 2007.
Accepted for publication December 12, 2007.

The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Fetal Distribution of Glyburide in the Pregnant Mouse - An OPRU Network and UW SCOR Study

Lin Zhou 1, Suresh Babu Naraharisetti 1, Honggang Wang 1, Jashvant D. Unadkat 1, Mary F. Hebert 1, Qingcheng Mao 1*

1 University of Washington

* Address correspondence to: E-mail: qmao{at}u.washington.edu

Abstract

BCRP is most abundantly expressed in the apical membrane of placental syncytiotrophoblasts, suggesting that it may protect the fetus by impeding drug penetration across the placental barrier. Glyburide (GLB) is an antidiabetic drug routinely used to treat gestational diabetes. In this study, we first examined if GLB is a BCRP/Bcrp1 substrate. The intracellular [3H]-GLB concentrations in MDCK/BCRP cells were significantly lower than those in MDCK/vector cells. The addition of 10 µM FTC, a specific BCRP inhibitor, significantly increased the intracellular [3H]-GLB concentrations approximately 2-fold in MDCK/BCRP cells, but had no effect on those in MDCK/vector cells. Similar results were obtained using MDCKII parent and MDCKII/Bcrp1 cells. GLB was also shown to be a BCRP/Bcrp1 substrate in transwell transport experiments. We then examined if Bcrp1 limits fetal distribution of GLB in the pregnant mouse. GLB was administered by retro-orbital injection to the wild-type and Bcrp1-/- pregnant mice. The maternal plasma samples and fetuses were collected at various times (0.5 - 240 min) after drug administration. The GLB concentrations in the maternal plasma samples and homogenates of fetal tissues were determined by HPLC/MS. While the maternal plasma AUCs of GLB in the wild-type and Bcrp1-/- pregnant mice were comparable, the fetal AUC of GLB in the Bcrp1-/- pregnant mice was approximately 2 times greater than that in the wild-type pregnant mice. These results suggest that GLB is a BCRP/Bcrp1 substrate, and Bcrp1 significantly limits fetal distribution of GLB in the pregnant mouse, but has only a minor effect on the systemic clearance of the drug.


Key words: MDR/p-Glycoprotein, Liver transporters


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
V. Petrovic, J.-H. Wang, and M. Piquette-Miller
Effect of Endotoxin on the Expression of Placental Drug Transporters and Glyburide Disposition in Pregnant Rats
Drug Metab. Dispos., September 1, 2008; 36(9): 1944 - 1950.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics